ReviewJournal of translational medicine2020
Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era.
Review in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer.Journal of translational medicine · 2024Pooled it
- LEF1-AS1 Deregulation in the Peripheral Blood of Patients with Persistent Post-COVID Symptoms.International journal of molecular sciences · 2025Article
- The COVID-19 legacy: consequences for the human DNA methylome and therapeutic perspectives.GeroScience · 2025Review
- Progress and trends in myocardial infarction-related long non-coding RNAs: a bibliometric analysis.Frontiers in molecular biosciences · 2024Review
- HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the peripheral blood mononuclear cells of COVID-19 patients.Journal of translational medicine · 2023Article
- Alterations in Circulating miRNA Levels after Infection with SARS-CoV-2 Could Contribute to the Development of Cardiovascular Diseases: What We Know So Far.International journal of molecular sciences · 2023Review
- Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality.Scientific reports · 2022Article
- Insights into Cardiovascular Defects and Cardiac Epigenome in the Context of COVID-19.Epigenomes · 2022Review
- Role of microRNAs in COVID-19 with implications for therapeutics.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Non-coding RNAs and their bioengineering applications for neurological diseases.Bioengineered · 2021Review
- SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad.International journal of molecular sciences · 2021Review
- miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- miRNAs; a novel strategy for the treatment of COVID-19.Cell biology international · 2021Review
- Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.Virus research · 2021Article
- Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.bioRxiv : the preprint server for biology · 2021Article
- OverCOVID: an integrative web portal for SARS-CoV-2 bioinformatics resources.Journal of integrative bioinformatics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
COronaVIrus Disease 19 (COVID-19) is caused by the infection of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2). Although the main clinical manifestations of COVID-19 are respiratory, many patients also display acute myocardial injury and chronic damage to the cardiovascular system. Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies. The homeostasis of the cardiovascular system requires a tight regulation of the gene expression, which is controlled by multiple types of RNA molecules, including RNA encoding proteins (messenger RNAs) (mRNAs) and those lacking protein-coding potential, the noncoding-RNAs. In the last few years, dysregulation of noncoding-RNAs has emerged as a crucial component in the pathophysiology of virtually all cardiovascular diseases. Here we will discuss the potential role of noncoding RNAs in COVID-19 disease mechanisms and their possible use as biomarkers of clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.